- Home
- IAE vs AGEN Comparison
IAE vs AGEN Comparison
Compare IAE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAE
- AGEN
- Stock Information
- Founded
- IAE 2007
- AGEN 1994
- Country
- IAE United States
- AGEN United States
- Employees
- IAE N/A
- AGEN N/A
- Industry
- IAE Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAE Finance
- AGEN Health Care
- Exchange
- IAE Nasdaq
- AGEN Nasdaq
- Market Cap
- IAE 65.2M
- AGEN 52.6M
- IPO Year
- IAE N/A
- AGEN 2000
- Fundamental
- Price
- IAE $6.30
- AGEN $2.91
- Analyst Decision
- IAE
- AGEN Buy
- Analyst Count
- IAE 0
- AGEN 4
- Target Price
- IAE N/A
- AGEN $8.00
- AVG Volume (30 Days)
- IAE 46.3K
- AGEN 845.0K
- Earning Date
- IAE 01-01-0001
- AGEN 05-12-2025
- Dividend Yield
- IAE 10.21%
- AGEN N/A
- EPS Growth
- IAE N/A
- AGEN N/A
- EPS
- IAE N/A
- AGEN N/A
- Revenue
- IAE N/A
- AGEN $103,463,000.00
- Revenue This Year
- IAE N/A
- AGEN $4.03
- Revenue Next Year
- IAE N/A
- AGEN $5.57
- P/E Ratio
- IAE N/A
- AGEN N/A
- Revenue Growth
- IAE N/A
- AGEN N/A
- 52 Week Low
- IAE $5.31
- AGEN $1.38
- 52 Week High
- IAE $6.45
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- IAE 61.98
- AGEN 59.81
- Support Level
- IAE $6.19
- AGEN $2.87
- Resistance Level
- IAE $6.33
- AGEN $3.16
- Average True Range (ATR)
- IAE 0.08
- AGEN 0.35
- MACD
- IAE 0.03
- AGEN 0.02
- Stochastic Oscillator
- IAE 90.24
- AGEN 56.25
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).